Source-grounded facts extracted from Pediatrix Medical Group, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Pediatrix Medical Group, Inc. shareholders approved Approval of the Second Amended and Restated 2008 Incentive Compensation Plan (increase in shares) at the 2026-05-07 meeting.
“Proposal 4: The Plan was approved by the Company’s shareholders, by the votes set forth in the table below: For Against Abstained Broker Non-Vote 65,912,243 6,303,675 18,413 5,095,808”
Pediatrix Medical Group, Inc. shareholders approved Advisory vote on executive compensation (say-on-pay) at the 2026-05-07 meeting.
“Proposal 3: The Company’s shareholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers for the 2025 fiscal year, by the votes set forth in the table below: For Against Abstained Broker Non-Vote 70,257,832 1,960,931 15,568 5,095,808”
Pediatrix Medical Group, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026 at the 2026-05-07 meeting.
“Proposal 2: The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year was ratified by the Company’s shareholders, by the votes set forth in the table below: For Against Abstained Broker Non-Vote 75,519,473 1,794,278 16,388 0”
Pediatrix Medical Group, Inc. shareholders approved Election of Directors at the 2026-05-07 meeting.
“Proposal 1: All of the nominees for the Company’s Board of Directors were elected to serve until the Company’s 2027 Annual Shareholders’ Meeting or until their respective successors are elected and qualified, by the votes set forth in the table below: Name For Against Abstained Broker Non-Vote Laura A. Linynsky 71,249,187 967,057 18,087 5,095,808 Thomas A. McEachin 70,107,436 2,093,168 33,727 5,095,808 Kurt D. Newman, M.D. 71,922,039 256,292 56,000 5,095,808 Mark S. Ordan 69,958,141 2,259,130 17,060 5,095,808 Michael A. Rucker 70,689,577 1,523,843 20,911 5,095,808 Guy P. Sansone 70,738,837 1,475,369 20,125 5,095,808 John M. Starcher, Jr. 46,296,745 25,909,618 27,968 5,095,808 Shirley A. Weis 70,725,919 1,478,539 29,873 5,095,808 Sylvia J. Young 71,257,572 963,152 13,607 5,095,808”
Pediatrix Medical Group, Inc. reported three months ended March 31, 2026 results: revenue $476 million, net income $30 million, EPS $0.36 per share. Guidance reaffirmed.
“ended March 31, 2026. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.44. For the 2026 first quarter, Pediatrix reported the following results: • Net revenue of $476 million; • Net income of $30 million; and • Adjusted EBITDA of $58 million. “Our first quarter operating results exceeded our expectations, driven by top-line growth,” said Mark S.”
Dr. James D. Swift departed as other_named_officer at Pediatrix Medical Group, Inc..
“succeeding Dr. James D. Swift.”
Mark S. Ordan was appointed as Chief Executive Officer at Pediatrix Medical Group, Inc..
“appointed Mr. Mark S. Ordan to serve as the Company’s Chief Executive Officer and principal executive officer, succeeding Dr. James D. Swift.”
Curtis B. Pickert changed role as Executive Vice President, Chief Physician Executive at Pediatrix Medical Group, Inc..
“the Company announced that Curtis B. Pickert, M.D. has transitioned from his role as the Company’s Executive Vice President, Chief Operating Officer and will now serve as Pediatrix’s Executive Vice President, Chief Physician Executive, effective as of August 1, 2024.”
Mary Ann E. Moore was appointed as Chief Administrative Officer at Pediatrix Medical Group, Inc..
“The Company also announced that the Board has appointed Ms. Mary Ann E. Moore to serve as the Company’s Chief Administrative Officer, in addition to her existing roles as the Company’s Executive Vice President, General Counsel and Secretary, effective as of August 1, 2024.”
Kasandra Rossi was appointed as Executive Vice President, Chief Financial Officer and Treasurer at Pediatrix Medical Group, Inc..
“On August 6, 2024, the Company announced that its board of directors (the “Board”) has appointed Ms. Kasandra Rossi, who currently serves as the Company’s Senior Vice President, Financial Reporting and Assistant Treasurer, to succeed Mr. C. Marc Richards as Executive Vice President, Chief Financial Officer (“CFO”) and Treasurer of the Company.”
C. Marc Richards was terminated as Executive Vice President, Chief Financial Officer and Treasurer at Pediatrix Medical Group, Inc..
“Mr. Richards’ transition from his role as Executive Vice President, CFO and Treasurer is a termination without “Cause” pursuant to that certain Amended and Restated Employment Agreement”
Lee A. Wood departed as Executive Vice President, National and Market Operations at Pediatrix Medical Group, Inc..
“On June 17, 2024, Pediatrix Medical Group, Inc., a Florida corporation (the “Company”), notified Mr. Lee. A Wood that the Company was eliminating the role of Executive Vice President, National and Market Operations, effective as of July 5, 2024 (the “Effective Date”), as part of the Company’s previously announced continued focus on operating efficiency.”
Pediatrix Medical Group, Inc. reported the three months ended March 31, 2024 results: revenue $495.1 million, net income $4.0 million, EPS $0.05 per diluted share. Guidance reaffirmed.
“ended March 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.20. For the 2024 first quarter, Pediatrix reported the following results: • Net revenue of $495 million; • Net income of $4 million; and • Adjusted EBITDA of $37 million. “Our first quarter operating results were in line with our expectations,” said James D. Swift, M.D., Chief”
Pediatrix Medical Group, Inc. entered into Master Services Agreement with Guidehouse Managed Services LLC valued at enterprise revenue cycle management services; eight-year initial term; successive two-year extension (effective 2024-04-19).
“On April 19, 2024, Pediatrix Medical Group, Inc., a Florida corporation (the “Company”), through PMG Services, Inc., a Florida corporation and wholly-owned subsidiary of the Company (“PMG Services”), entered into a Master Services Agreement (the “Agreement”) with Guidehouse Managed Services LLC (“Guidehouse”), a Delaware limited liability company, pursuant to which Guidehouse will provide certain enterprise revenue cycle management services for the Company.”
Pediatrix Medical Group, Inc. reported the year ended December 31, 2023 results: revenue $1.99 billion.
“For the year ended December 31, 2023, Pediatrix generated revenue from continuing operations of $1.99 billion, compared to $1.97 billion for the prior year.”
Pediatrix Medical Group, Inc. reported the three months ended December 31, 2023 results: revenue $496 million, net income Loss from continuing operations of $124 million, EPS loss from continuing operations of $1.50 per diluted share.
“For the 2023 fourth quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $496 million; • Loss from continuing operations of $124 million; and • Adjusted EBITDA of $51 million.”
Pediatrix Medical Group, Inc. reported financial results for nine months ended September 30, 2023.
“On November 2, 2023, Pediatrix Medical Group, Inc., a Florida corporation (the “Company”), issued a press release announcing the results of its operations for the three months and nine months ended September 30, 2023 (the “Third Quarter Release”). A copy of the Third Quarter Release is attached hereto as Exhibit 99.1 and is hereby incorporated in this Current Report by reference.”
Pediatrix Medical Group, Inc. reported financial results for three months ended September 30, 2023.
“On November 2, 2023, Pediatrix Medical Group, Inc., a Florida corporation (the “Company”), issued a press release announcing the results of its operations for the three months and nine months ended September 30, 2023 (the “Third Quarter Release”). A copy of the Third Quarter Release is attached hereto as Exhibit 99.1 and is hereby incorporated in this Current Report by reference.”
Pediatrix Medical Group, Inc. reported six months ended June 30, 2023 results: revenue $991.6 million, net income $42.5 million, EPS $0.52 per share.
“Operating Results from Continuing Operations – Six Months Ended June 30, 2023 For the six months ended June 30, 2023, Pediatrix generated revenue from continuing operations of $991.6 million, compared to $968.3 million for the prior-year period. Adjusted EBITDA from continuing operations for the six months ended June 30, 2023 was $99.2 million, compared to $116.2”
Pediatrix Medical Group, Inc. reported three months ended June 30, 2023 results: revenue $500.6 million, net income $28.3 million, EPS $0.34 per diluted share.
“reported Adjusted EPS from continuing operations of $0.39. For the 2023 second quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $501 million; • Income from continuing operations of $28 million; and • Adjusted EBITDA of $59 million. “Our second quarter operating results were in line with our expectations and reflect”
Pediatrix Medical Group, Inc. shareholders approved Advisory vote on frequency of future advisory votes on executive compensation at the 2023-05-11 meeting.
“Proposal 4: The Company's shareholders indicated, on a non-binding, advisory basis, a preference to hold future advisory votes on executive compensation every year, by the votes set forth in the table below: One Year Two Year Three Year Abstained Broker Non-Vote 71,890,793 60,488 3,922,750 35,197 2,770,115”
Pediatrix Medical Group, Inc. shareholders approved Advisory vote on executive compensation for 2022 fiscal year at the 2023-05-11 meeting.
“Proposal 3: The Company’s shareholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers for the 2022 fiscal year, by the votes set forth in the table below: For Against Abstained Broker Non-Vote 73,569,327 2,311,935 27,966 2,770,115”
Pediatrix Medical Group, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2023 at the 2023-05-11 meeting.
“Proposal 2: The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2023 fiscal year was ratified by the Company’s shareholders, by the votes set forth in the table below: For Against Abstained Broker Non-Vote 74,381,705 4,272,655 24,983 0”
Pediatrix Medical Group, Inc. shareholders approved Election of Directors at the 2023-05-11 meeting.
“Proposal 1: All of the nominees for the Company’s Board of Directors were elected to serve until the Company’s 2024 Annual Shareholders’ Meeting or until their respective successors are elected and qualified, by the votes set forth in the table below: Name For Against Abstained Broker Non-Vote Laura A. Linynsky 74,814,862 1,062,561 31,805 2,770,115 Thomas A. McEachin 74,748,365 1,131,638 29,225 2,770,115 Mark S. Ordan 73,978,210 1,904,201 26,817 2,770,115 Michael A. Rucker 68,578,436 7,298,897 31,895 2,770,115 Guy P. Sansone 75,113,470 764,042 31,716 2,770,115 John M. Starcher, Jr. 74,815,365 1,061,736 32,127 2,770,115 James D. Swift, M.D. 75,468,494 411,167 29,567 2,770,115 Shirley A. Weis 74,298,008 1,579,336 31,884 2,770,115”
Sylvia Young was appointed as Director at Pediatrix Medical Group, Inc..
“increased the size of the Company’s Board to nine (9) members and appointed Ms. Sylvia Young to serve as a Director of the Company, each effective as of May 12, 2023.”
Pediatrix Medical Group, Inc. reported the three months ended March 31, 2023 results: revenue $491 million, net income $14 million, EPS $0.17 per share.
“Pediatrix Medical Group, Inc. (NYSE: MD) , the nation’s leading provider of highly specialized health care for women, children and babies , today reported earnings from continuing operations of $0.17 per share for the three months ended March 31, 2023. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.23. For the 2023 first quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $491 million; • Income from continuing operations of $14 million; and • Adjusted EBITDA of $40 million.”
James D. Swift was elected as Director at Pediatrix Medical Group, Inc..
“elected James D. Swift, M.D., the Company’s Chief Executive Officer, to the Board to fill a vacancy created by the resignation of Roger J. Medel M.D.”
Roger J. Medel resigned as Director at Pediatrix Medical Group, Inc..
“who resigned from the Board effective March 7, 2023.”
Pediatrix Medical Group, Inc. reported financial results for the twelve months ended December 31, 2022.
“On February 17, 2023, Pediatrix Medical Group, Inc., a Florida corporation (the “Company”), issued a press release announcing the results of its operations for the three months and twelve months ended December 31, 2022 (the “Fourth Quarter Release”).”
Pediatrix Medical Group, Inc. reported financial results for the three months ended December 31, 2022.
“On February 17, 2023, Pediatrix Medical Group, Inc., a Florida corporation (the “Company”), issued a press release announcing the results of its operations for the three months and twelve months ended December 31, 2022 (the “Fourth Quarter Release”).”
Mark S. Ordan was appointed as Executive Chair of the Board at Pediatrix Medical Group, Inc..
“Mr. Mark S. Ordan, who has been appointed as the Executive Chair of the Board”
James D. Swift, M.D. was appointed as Chief Executive Officer at Pediatrix Medical Group, Inc..
“appointed James D. Swift, M.D., as the Company’s Chief Executive Officer and principal executive officer to succeed Mr. Mark S. Ordan”
Pediatrix Medical Group, Inc. reported the nine months ended September 30, 2022 results: revenue $1.46 billion.
“For the nine months ended September 30, 2022, Pediatrix generated revenue from continuing operations of $1.46 billion, compared to $1.41 billion for the prior-year period.”
Pediatrix Medical Group, Inc. reported the three months ended September 30, 2022 results: revenue $490 million, net income $29 million, EPS $0.35 per diluted share.
“Pediatrix Medical Group, Inc. (NYSE: MD) , the nation’s leading provider of highly specialized health care for women, children and babies , today reported earnings from continuing operations of $0.35 per share for the three months ended September 30, 2022. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.40. For the 2022 third quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $490 million; • Income from continuing operations of $29 million; and • Adjusted EBITDA of $58 million.”
Mary Ann Moore was appointed as Executive Vice President, General Counsel and Secretary at Pediatrix Medical Group, Inc..
“Ms. Mary Ann Moore, the Company’s Executive Vice President, Chief Enterprise Risk and Legal Operations Officer, will be appointed the Company’s Executive Vice President, General Counsel and Secretary upon Mr. Andreano’s transition from his current role.”
Dominic J. Andreano changed role as Executive Vice President, General Counsel and Secretary at Pediatrix Medical Group, Inc..
“On September 19, 2022, Pediatrix Medical Group, Inc., a Florida corporation (the “Company”), announced that Dominic J. Andreano, the Company’s Executive Vice President, General Counsel and Secretary, would transition from such position, effective on or about October 14, 2022 (the “Effective Date”).”
James D. Swift was appointed as Chief Operating Officer at Pediatrix Medical Group, Inc..
“On May 12, 2022, Mednax, Inc., a Florida corporation (the “Company”), appointed James D. Swift, M.D. as an Executive Vice President and the Company’s Chief Operating Officer.”
Roger Mack Hinson changed role as President of the Company’s Pediatrix and Obstetrix Medical Group at Pediatrix Medical Group, Inc..
“On February 23, 2022, Mednax, Inc., a Florida corporation (the “Company”), announced that Roger Mack Hinson, M.D., President of the Company’s Pediatrix and Obstetrix Medical Group, would transition from such position, effective as of June 1, 2022 (the “Effective Date”).”
John C. Pepia changed role as Senior Vice President and Chief Accounting Officer at Pediatrix Medical Group, Inc..
“Mr. John C. Pepia, who previously served as the Company’s Principal Accounting Officer, will continue to serve as the Company’s Senior Vice President and Chief Accounting Officer.”
C. Marc Richards changed role as Principal Accounting Officer at Pediatrix Medical Group, Inc..
“On November 16, 2021, the Board of Directors (the “Board”) of Mednax, Inc., a Florida corporation (the “ Company ”), determined that Mr. C. Marc Richards, currently the Executive Vice President and Chief Financial Officer and Principal Financial Officer of the Company, would also serve as Company’s Principal Accounting Officer, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.